SAN DIEGO, Aug. 9, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP, is investigating potential claims against Amarin Corporation plc ("Amarin") (AMRN) for violations of federal securities laws.
On August 8, 2019, Amarin announced that it received notice from the FDA that it plans to hold an advisory committee meeting, tentatively scheduled for November 14, 2019, in connection with its review of the pending supplemental new drug application for expansion of Vascepa. The Company stated that the FDA's deadline for making an approval decision on Vascepa would likely be extended.
Just one week earlier, on July 31, 2019, Amarin said it was unlikely that the FDA would proceed with an advisory panel review regarding approval of Vascepa and anticipated a September 28, 2019 approval.
Following this news, Amarin stock was trading down over 20% in premarket trading on August 9, 2019.
If you recently purchased Amarin and lost money, realized or unrealized on your investment, and are interested in learning more about the investigation or your legal rights and remedies, please contact Jim Baker (firstname.lastname@example.org) by email or phone at 619-814-4471. If emailing, please include a phone number.
Additionally, you can [click here to join this action]. There is no cost or obligation to you.
About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York, and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.